MDMA-Assisted Psychotherapy

Our highest priority project is funding clinical trials of 3,4-methylenedioxymethamphetamine (MDMA) as a tool to assist psychotherapy for the treatment of posttraumatic stress disorder (PTSD).

We have also sponsored clinical trials of MDMA-assisted psychotherapy for anxiety associated with life-threatening illness, and for social anxiety in autistic adults, LSD-assisted psychotherapy for anxiety, and medical marijuana for PTSD in veterans of war. We have sponsored observational studies for ibogaine therapy for drug addiction and ayahuasca-assisted treatment for drug addiction and PTSD.

Our Education Programs

In addition to our clinical research programs, MAPS provides harm reduction training and services through the Zendo Project, advocates for reducing barriers to scientific research with psychedelics and marijuana, and curates educational events and webinars.